Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
- PMID: 32149772
- PMCID: PMC7213617
- DOI: 10.1097/CM9.0000000000000790
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
Conflict of interest statement
None.
References
-
- National Health Commission of the People's Republic of China. Guidelines for Diagnosis and Treatment of Novel Coronavirus Pneumonia (Trial Version 5) 2020. Available from: http://www.gov.cn/zhengce/zhengceku/2020-02/05/5474791/files/de44557832a.... [Accessed February 6, 2020] - PMC - PubMed
-
- Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther 2016; 21:455–459. doi: 10.3851/IMP3002. - PubMed
-
- Spanakis N, Tsiodras S, Haagmans BL, Raj VS, Pontikis K, Koutsoukou A, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 2014; 44:528–532. doi: 10.1016/j.ijantimicag.2014.07.026. - PMC - PubMed
-
- Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Yin Z, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, China. J Med Microbiol 2003; 52:715–720. doi: 10.1099/jmm.0.05320-0. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
